Overview

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Leonard Feiner, MD, PhD
Collaborator:
NJ Retina (Retina Associates of New Jersey)
Treatments:
Ranibizumab